Comparison of Diagnostic Accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A Lesion-by-lesion Analysis in Patients with Metastatic Neuroendocrine Tumours

Overview

Journal Eur Radiol

Specialty Radiology

Date 2015 Jul 12

PMID 26162577

Citations 43

Authors

S Van Binnebeek

B Vanbilloen

K Baete

C Terwinghe

M Koole

F M Mottaghy

P M Clement

L Mortelmans

K Bogaerts

K Haustermans

K Nackaerts

E Van Cutsem

C Verslype

A Verbruggen

C M Deroose

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare the diagnostic accuracy of (111)In-pentetreotide-scintigraphy with (68)Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality.

Methods: Fifty-three metastatic-NET-patients underwent (111)In-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body (68)Ga-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities.

Results: Significantly more lesions were detected on (68)Ga-DOTATOC-PET/CT versus (111)In-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p<0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton.

Conclusion: Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to (111)In-pentetreotide SPECT.

Key Points: Somatostatin receptor PET is superior to SPECT in detecting NET metastases. PET is the scintigraphic method for accurate depiction of NET tumour burden. The sensitivity of PET is twofold higher than the sensitivity of SPECT.

Citing Articles

Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging.

Fonseca A, Sereno J, Almeida S, Ferreira H, Hrynchak I, Falcao A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39909885 DOI: 10.1007/s00259-025-07116-2.

Small cell lung cancer and neuroendocrine tumours.

Pandjarova I, Mercieca D, Gijtenbeek R, Pereira J, Fantin A, Castaldo N Breathe (Sheff). 2024; 20(3):240004.

PMID: 39534494 PMC: 11555584. DOI: 10.1183/20734735.0004-2024.

A Case of Pancreatic Neuroendocrine Tumor with Liver Metastases Demonstrating the Possibility of Enhanced ACTH Production by the SACI Test.

Mori H, Tamura M, Ogawa R, Kimata Y, Endo S, Sekine K Case Rep Endocrinol. 2024; 2024:5923680.

PMID: 38681235 PMC: 11055651. DOI: 10.1155/2024/5923680.

Head-to-head comparison between [Ga]Ga-DOTA-NOC and [F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas.

He Q, Zhang Z, Zhang L, Zhang B, Long Y, Zhang Y Eur J Nucl Med Mol Imaging. 2024; 51(7):1989-2001.

PMID: 38300262 DOI: 10.1007/s00259-024-06622-z.

Pancreatic Neuroendocrine Tumor (Pan-NET) Presented by Abdominal Pain: A Case Report and Literature Review.

Regolo M, Cardaci N, Salmeri C, Laudani A, Colaci M, Ippolito M J Clin Med. 2023; 12(20).

PMID: 37892755 PMC: 10607714. DOI: 10.3390/jcm12206617.

References

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M . Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007; 34(10):1617-26. DOI: 10.1007/s00259-007-0450-1. View

Schreiter N, Brenner W, Nogami M, Buchert R, Huppertz A, Pape U . Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 39(1):72-82. DOI: 10.1007/s00259-011-1935-5. View

Geijer H, Breimer L . Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013; 40(11):1770-80. DOI: 10.1007/s00259-013-2482-z. View

Reubi J, Waser B . Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003; 30(5):781-93. DOI: 10.1007/s00259-003-1184-3. View

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C . 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007; 48(4):508-18. DOI: 10.2967/jnumed.106.035667. View

Teunissen J, Krenning E, de Jong F, de Rijke Y, Feelders R, van Aken M . Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging. 2009; 36(11):1758-66. PMC: 2764054. DOI: 10.1007/s00259-009-1151-8. View

Haug A, Cindea-Drimus R, Auernhammer C, Reincke M, Wangler B, Uebleis C . The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med. 2012; 53(11):1686-92. DOI: 10.2967/jnumed.111.101675. View

Van Binnebeek S, Deroose C, Baete K, Terwinghe C, Vanbilloen B, Koole M . Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. J Clin Oncol. 2011; 29(19):e579-81. DOI: 10.1200/JCO.2010.34.3384. View

Kowalski J, Henze M, Schuhmacher J, Macke H, Hofmann M, Haberkorn U . Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5(1):42-8. DOI: 10.1016/s1536-1632(03)00038-6. View

10.

Van Essen M, Krenning E, Kam B, de Jong M, Valkema R, Kwekkeboom D . Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009; 5(7):382-93. DOI: 10.1038/nrendo.2009.105. View

11.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

12.

Kwekkeboom D, Krenning E, Scheidhauer K, Lewington V, Lebtahi R, Grossman A . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009; 90(2):184-9. DOI: 10.1159/000225946. View

13.

Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Koole M, Mottaghy F . Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2014; 41(6):1141-57. DOI: 10.1007/s00259-013-2670-x. View

14.

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

15.

Kwekkeboom D, Kooij P, Bakker W, Macke H, Krenning E . Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med. 1999; 40(5):762-7. View

16.

Meyer G, Macke H, Schuhmacher J, Knapp W, Hofmann M . 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004; 31(8):1097-104. DOI: 10.1007/s00259-004-1486-0. View

17.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

18.

Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V . Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012; 42(1):80-7. DOI: 10.1007/s12020-012-9631-1. View

19.

Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L . Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med. 2012; 27(1):74-7. DOI: 10.1007/s12149-012-0651-y. View

20.

Koukouraki S, Strauss L, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N . Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006; 33(4):460-6. DOI: 10.1007/s00259-005-0006-1. View